Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Balachandran, Vinod P., Cavnar, Michael J., Zeng, Shan, Bamboat, Zubin M., Ocuin, Lee M., Obaid, Hebroon, Sorenson, Eric C., Popow, Rachel, Ariyan, Charlotte, Rossi, Ferdinand, Besmer, Peter, Guo, Tianhua, Antonescu, Cristina R., Taguchi, Takahiro, Yuan, Jianda, Wolchok, Jedd D., Allison, James P., DeMatteo, Ronald P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278279/
https://ncbi.nlm.nih.gov/pubmed/21873989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.2438
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge